Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive raw market data from a plurality of lines of business of an enterprise organization. Thereafter, the computing platform may preprocess the raw market data to obtain enterprise level market data, execute synthetic DNA stranding of the enterprise level market data to obtain synthetic DNA stranded market data, run the synthetic DNA stranded market data through one or more market volatility models, and compile results from the market volatility models on the synthetic DNA stranded market data. The computing platform may transmit results from the market volatility models on the synthetic DNA stranded market data. The transmitted results may be configured to display a market application interface that includes market volatility forecasting parameters based on results of the market volatility models.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may initiate a set of instructions associated with performing an action on a synthetic DNA market data set associated with a plurality of lines of business across an enterprise organization. Thereafter, the computing platform may convert the set of instructions to a mutant nucleotide sequence, and insert the mutant nucleotide sequence into the synthetic DNA market data set. The computing platform may extract, using the mutant nucleotide sequence, target information from the synthetic DNA market data set, and validate the target information to detect one or more anomalies. The computing platform may remove the one or more data anomalies, and subsequently output a validated synthetic DNA market data set to a synthetic DNA client server.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive market data from a plurality of lines of business across an enterprise, wherein the market data is received in a raw, uncompressed format. Thereafter, the computing platform may assimilate and preprocess the market data to output vectored market data. The computing platform may perform a synthetic DNA stranding process on the vectored market data to create one or more strands of synthetic DNA market data, and output the one or more strands of synthetic DNA market data to a synthetic DNA client server, wherein the one or more stands of synthetic DNA market data is configured for input in a market volatility prediction model.

Abstract: Aspects of the disclosure relate to a cloud-based parallel processing and cognitive learning computing platform. A computing platform may receive query data comprising a plurality of requested metrics. The computing platform may select a secondary node to process the query request from a plurality of secondary nodes of the computing platform. The computing platform may send the query request to the secondary node. The computing platform may send a request to generate a metric mapping table for a first requested metric to a cognitive learning module of the computing platform. The cognitive learning module may generate the metric mapping table for the first requested metric using neuron clusters that comprise a plurality of unique programmable quadratic function neurons. The computing platform may calculate a value for the first requested metric based on the metric mapping table.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separating a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space and a cooling tube. In some examples, the UV light source is configured to emit light with wavelengths with a desired intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: Described herein are compositions and methods of treating gastrointestinal diseases and disorders such as irritable bowel syndrome and small intestinal bacterial overgrowth.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive market data from a plurality of lines of business across an enterprise, wherein the market data is received in a raw, uncompressed format. Thereafter, the computing platform may assimilate and preprocess the market data to output vectored market data. The computing platform may perform a synthetic DNA stranding process on the vectored market data to create one or more strands of synthetic DNA market data, and output the one or more strands of synthetic DNA market data to a synthetic DNA client server, wherein the one or more stands of synthetic DNA market data is configured for input in a market volatility prediction model.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may initiate a set of instructions associated with performing an action on a synthetic DNA market data set associated with a plurality of lines of business across an enterprise organization. Thereafter, the computing platform may convert the set of instructions to a mutant nucleotide sequence, and insert the mutant nucleotide sequence into the synthetic DNA market data set. The computing platform may extract, using the mutant nucleotide sequence, target information from the synthetic DNA market data set, and validate the target information to detect one or more anomalies. The computing platform may remove the one or more data anomalies, and subsequently output a validated synthetic DNA market data set to a synthetic DNA client server.

Abstract: Aspects of the disclosure relate to using synthetic DNA stranding and mutant nucleotide processes to conduct enterprise market volatility predictions. In some embodiments, a computing platform may receive raw market data from a plurality of lines of business of an enterprise organization. Thereafter, the computing platform may preprocess the raw market data to obtain enterprise level market data, execute synthetic DNA stranding of the enterprise level market data to obtain synthetic DNA stranded market data, run the synthetic DNA stranded market data through one or more market volatility models, and compile results from the market volatility models on the synthetic DNA stranded market data. The computing platform may transmit results from the market volatility models on the synthetic DNA stranded market data. The transmitted results may be configured to display a market application interface that includes market volatility forecasting parameters based on results of the market volatility models.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: The invention provides for methods and kits for processing viscous biological samples such as intestinal fluids and aspirates. Increased numbers of microorganisms are extracted by the methods and kits of this invention, and thus, DNA extraction and analysis can be performed.

Abstract: The present invention relates to, in part, methods and compositions for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS). Particularly, modified-release formulations comprising at least one antimethanogenic statin are provided which release the antimethanogenic statin in the intestines.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.

Abstract: The invention described herein provides for methods and systems for determining, selecting, and/or treating diseases and conditions caused by or associated with high quantities of methanogens in a subject, or diseases and conditions caused by or associated with low quantities of methanogens in a subject. In various embodiments, a therapy to inhibit the growth of methanogens or to promote the growth of methanogens are selected and/or administered to a subject in need thereof.